DarioHealth (NASDAQ:DRIO) Second Quarter 2025 Results
Key Financial Results
- Revenue: US$5.37m (down 14% from 2Q 2024).
- Net loss: US$18.6m (loss widened by 451% from 2Q 2024).
- US$0.37 loss per share (further deteriorated from US$0.085 loss in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
DarioHealth EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 22%. Earnings per share (EPS) exceeded analyst estimates by 23%.
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare Services industry in the US.
Performance of the American Healthcare Services industry.
The company's shares are down 15% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 4 warning signs for DarioHealth (2 shouldn't be ignored!) that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if DarioHealth might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.